ATYR - Latest News
aTyr Pharma, Inc. (ATYR), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $38.8M. Beta to the broader market is 0.66.
The article list below shows the most recent ATYR headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ATYR Headlines
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
globenewswire.com - May 15, 2026
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June
aTyr Pharma to Participate in Upcoming Investor Conferences
globenewswire.com - May 13, 2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and dev
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
seekingalpha.com - May 12, 2026
aTyr Pharma, Inc.
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
marketbeat.com - May 11, 2026
aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U. S
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
globenewswire.com - May 11, 2026
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new
How News Affects ATYR Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ATYR's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ATYR news questions
- What is the latest ATYR news headline?
- The most recent ATYR headline (May 15, 2026) is "aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ATYR news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ATYR news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ATYR options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.